BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220524
DTEND;VALUE=DATE:20220527
DTSTAMP:20260515T180613
CREATED:20220125T090934Z
LAST-MODIFIED:20220125T114614Z
UID:32936-1653350400-1653609599@www.pharmajournalist.com
SUMMARY:Next Generation RNA Therapeutics Summit
DESCRIPTION:With novel RNA-based modalities having seen extraordinary development in the last 18 months\, there has never been a more important time for the RNA community to unite\, share learnings and accelerate the field towards successful proof of concept and effective therapeutic development. \nStay ahead of the curve with novel RNA therapeutics and vaccines that offer exceptional stability and durability whilst addressing key delivery\, pharmacology and scalability challenges to successfully translate safe and effective next generation RNA therapeutics into the clinic. \nThe Next Generation RNA Therapeutics Summit is the only meeting to deep dive into the specific challenges and opportunities associated with novel RNA modalities\, welcoming cutting-edge biotech giants such as Pfizer\, BioNTech\, Moderna Therapeutics and Replicate Bioscience to share unmissable insights on circular RNA\, tRNA and self-amplifying RNA therapeutics and vaccines. \nJoin 80+ thought leaders under one roof as they set the scene for next generation RNA therapeutics. This unique group of Directors\, Heads and VPs of RNA Therapeutics\, Chemistry\, Delivery and New Therapeutics will unite at this must-attend event for the RNA community. Don’t miss out! \nTo find out more\, visit: https://ter.li/0ei6ql
URL:https://www.pharmajournalist.com/event/next-generation-rna-therapeutics-summit/
LOCATION:Omni Parker House\, 60 School St\, Boston\, MA\, 02108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220524
DTEND;VALUE=DATE:20220527
DTSTAMP:20260515T180613
CREATED:20220207T101226Z
LAST-MODIFIED:20220207T101226Z
UID:33175-1653350400-1653609599@www.pharmajournalist.com
SUMMARY:4th Annual Cell Engager Summit
DESCRIPTION:4th Annual Cell Engager Summit  May 24-26\, 2022 | Boston\, MA \n\nThe 4th Annual Cell Engager Summit returns to bring you the latest on effectively targeting lymphocyte-restricted tumor-associated antigens to treat hematological malignancies\, including CD19\, CD20\, BCMA\, CD33\, and CD123. \n \nThis must-attend meeting will provide a comprehensive understanding of the development of multi-specific cell engaging therapeutics in liquid and solid tumor indications\, with the goal of bringing early-stage innovation to the clinic. \nLearn all there is to know about the immune cell engager landscape\, including clinical achievements\, potential response predictors\, and novel immune cell-based engager therapeutic discoveries. \nYou will leave this meeting with key steps to improving safety and efficacy in the solid tumor microenvironment through lower CRS\, greater dose\, and lower TMDD by targeting tumor antigens such as HER2 and EGFR\, and modifying co-stimulatory receptors (for example CD137/4-1BB\, CD28). \nEnsure your Cell Engager program reaches full clinical potential through learning from the pioneers of immunotherapy. \nTo know more visit: https://ter.li/d3i1x0
URL:https://www.pharmajournalist.com/event/4th-annual-cell-engager-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220524
DTEND;VALUE=DATE:20220527
DTSTAMP:20260515T180613
CREATED:20220405T114748Z
LAST-MODIFIED:20220406T094813Z
UID:33731-1653350400-1653609599@www.pharmajournalist.com
SUMMARY:Hippo Pathway Targeted Drug Development Summit
DESCRIPTION:It has long been understood that the Hippo pathway plays a critical role in the development of a wide range of diseases. Although once seen as an elusive pathway\, emerging novel data and research is forging a wider and more developed mechanistic understanding of it. New avenues have been opened to evolve the landscape of targetable nodes and therapeutic interventions\, from small molecule approaches to novel modalities targeting the TEAD transcription complex. \nWith the clear therapeutic potential of this highly attractive and targetable pathway\, investment\, collaboration\, and interest has flooded in through biopharma and academia – and what was once an unexploited space is now seeing an abundance of promising therapeutic interventions. \nThe inaugural Hippo Pathway Targeted Drug Development Summit has been established as the first and only industry dedicated forum focused on accelerating the mechanistic understanding and potential of the Hippo signaling pathway to enhance the discovery\, translation\, and clinical development of safe and effective drugs in oncology\, regenerative medicine and beyond. \nUniting the leading minds of large pharma\, biotech and academia\, this unrivalled conference will showcase the pioneering discoveries\, critical novel findings and promising clinical candidates drugging YAP\, TAZ & TEAD transcription factors and other high-value targets within the Hippo pathway. With Keynote sessions from Ikena Oncology\, Spring Works Therapeutics\, Cedilla and Vivace Therapeutics\, this is a unique opportunity to hear first-hand the development of novel YAP/TAZ-TEAD antagonists\, from discovery to the clinic. \nOver 80 key stakeholders from BridgeBio\, Cancer Research UK\, AstraZeneca\, Orion Pharma\, Faze Medicines\, Inventiva\, Zentalis Pharmaceuticals\, Basilea Pharmaceuticals and many more have already confirmed their places as the industry continues to unlock critical pieces of the puzzle in the understanding and exploitation of this signaling pathway. \nTogether\, we will unite to learn\, debate\, and discuss; leverage the therapeutic opportunity of this pathway; and critically address the huge unmet clinical need. \nTo know more visit: https://ter.li/4tdp3b
URL:https://www.pharmajournalist.com/event/hippo-pathway-targeted-drug-development-summit/
LOCATION:DoubleTree Suites by Hilton Hotel Boston\, 400 Soldiers Field Road\, Cambridge\, Boston\, MA\, 02134\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220525
DTEND;VALUE=DATE:20220528
DTSTAMP:20260515T180613
CREATED:20220126T092108Z
LAST-MODIFIED:20220126T092108Z
UID:32969-1653436800-1653695999@www.pharmajournalist.com
SUMMARY:ADC Analytical Development Summit
DESCRIPTION:As ADCs continue to see clinical success\, and as drug design becomes more complex\, regulatory scrutiny to ensure product quality is increasing. The trailblazing ADC Analytical Development Summit is the first and only industry focused meeting dedicated to addressing the unique challenges faced by analytical\, CMC\, QC\, process development and protein characterization experts working on ADCs. \nCovering the end-to-end development and application of analytical technologies in a phase-dependent manner\, this novel meeting will focus on enhancing ADC characterization\, understanding drug potency and demonstrating homogeneity to support regulatory requirements. \nWith the sharing of unique insights into novel method development\, CQAs\, bioassays\, DAR quantification and distribution\, and platform approaches\, this is your unmissable opportunity to get up to speed with this rapidly growing field and to support safe\, consistent and high quality ADC development. \nThrough a series of in-depth case studies\, interactive panel discussions and roundtables\, informative and enriching workshops\, and networking with likeminded individuals pioneering analytical development\, you’ll be equipped to advance your understanding of the safety\, identity\, potency\, purity and quality of your ADC. \nTo know more visit: https://ter.li/0ay4ao
URL:https://www.pharmajournalist.com/event/adc-analytical-development-summit/
LOCATION:Hyatt Regency Boston Cambridge\, 575 Memorial Drive\, Cambridge\, MA\, 02139\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220530
DTEND;VALUE=DATE:20220602
DTSTAMP:20260515T180613
CREATED:20220303T094518Z
LAST-MODIFIED:20220303T094518Z
UID:33420-1653868800-1654127999@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy Analytical Development Europe
DESCRIPTION:Uncover the Robust Analytical Methods to Guarantee Safe\, High Quality\, Consistent & Efficacious Gene Therapy Products \nIn the context of unprecedented gene therapy investment and clinical progress\, with mounting regulatory scrutiny\, Gene Therapy Analytical Development Europe will unite innovative biotech and pharma organisations to develop robust analytical tools to guarantee the consistency\, quality\, and safety of gene therapy products. \nWhether you’re looking for specific characterisation\, potency or infectivity approaches to improve your current analytical toolbox or if you’re seeking to understand how gene therapy analytics differ from other biologics you’ve worked on in the past\, this focused\, technical event will provide insights specifically on the unique analytical challenges posed by gene therapy vectors\, delivered by ‘boots on the ground’ scientists grappling with these challenges first-hand. \nJoin 150+ analytical pioneers to discover the realities of working with tools like dPCR\, AUC and HPLC\, as well as how and where these tools can be most effective in process development\, and what the European regulators expect in order to grant approval. Whether you’re working with AAV or lentiviral vectors\, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development. \nTo know more visit: https://ter.li/04rwmv
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-analytical-development-europe/
LOCATION:Victoria Park Plaza Hotel\, 239 Vauxhall Bridge Road\, Pimlico\, London\, SW1V 1EQ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220607
DTEND;VALUE=DATE:20220610
DTSTAMP:20260515T180613
CREATED:20220207T092209Z
LAST-MODIFIED:20220207T092209Z
UID:33157-1654560000-1654819199@www.pharmajournalist.com
SUMMARY:2nd Annual Gene Therapy Patient Engagement Summit
DESCRIPTION:Integrate the Patient Voice to Develop Safer & More Effective Gene Therapies That Are Meaningful to Patients \n \nAs investment in gene therapies continues to grow rapidly\, more effectively engaging patients throughout development has become a priority for any company serious about building safer and more meaningful gene therapy programs. \nIn this context\, the 2nd Annual Gene Therapy Patient Engagement Summit will unite patient advocacy and engagement leaders from gene therapy and gene editing drug developers\, patient groups and patients themselves to address the specific challenges of genetic therapy patient engagement\, generating actionable insights through detailed case studies and open\, honest discussions. \nJoin us to hear directly from companies and institutions including Spark Therapeutics\, Ultragenyx\, FDA\, Global Genes\, and CRISPR Therapeutics on key topics including managing expectations across gene therapy development\, navigating patient input on one-time transformative treatments with novel clinical trial designs combined with extensive follow-ups\, and developing educational materials on gene therapy to raise awareness in collaboration with patient advocacy organizations. Leverage their knowledge and experiences to ultimately ensure effective creation and implementation of patient-centric gene therapy programs. \nTo know more visit: https://ter.li/c9d6sy
URL:https://www.pharmajournalist.com/event/2nd-annual-gene-therapy-patient-engagement-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220613
DTEND;VALUE=DATE:20220615
DTSTAMP:20260515T180613
CREATED:20220303T102140Z
LAST-MODIFIED:20220303T102140Z
UID:33430-1655078400-1655251199@www.pharmajournalist.com
SUMMARY:Pre Filled Syringes West Coast
DESCRIPTION:SMi’s 6th Annual Conference\nPre-Filled Syringes West Coast\nJune 13 – 14\, 2022 | San Diego\, CA\, USA \nSESSING DEVICE DEVELOPMENT AND REGULATION FOR ADVANCED INNOVATION \nSMi is delighted to announce the 6th annual Pre-Filled Syringes West Coast conference\, to be held in San Diego. As part of SMi’s leading series of drug delivery device conferences\, the 2022 event will provide insights into the rapidly accelerating market of combination product development with industry\, device developer and regulatory perspectives. \n \nThe last year has seen major advances in device design and development with patient usability\, ease of use and safety remaining at the forefront. This upcoming conference will assess the industry movement towards enabling self-administration through advanced device design\, innovations in connectivity to aid the user\, and the increasing importance of biologics and novel drug product considerations for device development. Furthermore\, regulatory bodies and leaders from big pharma will give an international update on the fast-evolving industry landscape. As one of our most sought-after events\, this conference is not to be missed. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nBenefits of attending: \n\nDiscover the latest advances in innovative device design for user-centric drug delivery\nAssess evolving approaches to platforms for advanced combination product portfolios\nUncover the key considerations to ensure optimal lifecycle management for drug delivery devices\nExplore how the industry is evolving with global developments including case studies of sustainable practices for drug delivery devices and the industry’s role in mass vaccination campaigns\nEngage in interactive sessions reviewing the landscape of on-body injectors for large volume delivery and the role of connectivity for wearable devices\n\nChAiRs foR 2022: \nTina Rees\, Associate Director\, Human Factors\, Regeneron Pharmaceuticals \nNatalie Abts\, Head of Human Factors Engineering\, Genentech \nFeatured 2022 speakers include:  \n\nSriman Banerjee\, Head of Packaging Development & Commercial Device Engineering\, Takeda\nAmin Sedighiamiri\, Associate Director\, Device Development\, AstraZeneca\nJames Wabby\, Executive Director\, Head of Regulatory Strategy\, Emerging Technologies and Combination Products\, Abbvie\nKhaudeja Bano\, Executive Medical Director\, Combination Product Safety Head\, Amgen\nRachel poker\, Associate Director\, Human Factors\, AstraZeneca\nKristina Li\, Sr. Engineer II\, Technical Development\, Biogen\nsujani Nannapaneni\, Human Factors Principal Research Engineer\, Combination Product Development\, Abbvie\n\nWho should attend? \n\nDrug-delivery developers\nMedical Device Engineers\nPrimary Packaging material designers\nSecondary packagers\nSmart device developers\nTraining device developers\nDevice-safety solution providers\nDrug developers\n\nPrevious attendees include: \nAbbott Laboratories; AbbVie; Advanced Molding Technologies; Aegerion Pharmaceuticals; Ajinomoto Althea\, Inc.; Allergan; Allergen Inc; Almac Group; Amgen; Antares Pharma; Aptar Pharma; AstraZeneca; Baxter Healthcare; BCM Group LLC; BioMarin; Boehringer Ingelheim; Connecticut Spring & Stamping; Credence MedSystems\, Inc.; Execution Metrics\, Inc; Ferring Pharmaceuticals; Fresenius-Kabi; Genentech; Genentech\, Inc.; Gilead Sciences; Glenmark Pharmaceuticals; Harro Hofliger Verpackungsmaschinen GmbH; Inovio Pharmaceuticals; iO Lifesciences; Ionis Pharmaceuticals; Ionis Pharmaceuticals\, Inc.; Matchstick; MedImmune; MedImmune LLC; Medizap; Medtronic; Merck & Co.; Mitsubishi Gas Chemical Company\, Inc; Nemera; Nipro PharmaPackaging; NOVO Engineering\, Inc.; Novo Nordisk; Novo Nordisk A/S; One World DMG; Owen Mumford; Pfenex; Pfenex Inc; Pfizer CentreOne; RAUMEDIC INC; Regeneron; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals\, Inc.; Shire; Smithers Rapra; Steri-Tek; Stevanato Group S.p.A; Subcuject ApS; Suttons Creek Inc; Terumo Corporation; Terumo Medical Corporation; Terumo Pharmaceutical Solutions; UserWise\, Inc.; W. L. Gore & Associates\, Inc.; West Pharmaceutical Services; West Pharmaceutical Services\,; West Pharmaceuticals Services Inc; Worrell; Xeris Pharmaceuticals; ZebraSCI; zebrasci inc; ZEON CORPORATION; Zeon Specialty Materials ; Zeon Specialty Materials Inc \nFind out more here: http://www.prefilled-syringes-westcoast.com/ \nSMi Group offer direct access to key decision makers through tailored sponsorship\, exhibitor and delegate packages. For details contact Daniele Moreschi on +44 7498539226  \nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: rjones@smi-online.co.uk\nFollow us: @SMiPharm #SMiPFSUSA
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-west-coast-2022/
LOCATION:San Diego\, CA\, USA
ORGANIZER;CN="SMi Events":MAILTO:rjones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220614
DTEND;VALUE=DATE:20220617
DTSTAMP:20260515T180613
CREATED:20220202T094402Z
LAST-MODIFIED:20220202T094440Z
UID:33099-1655164800-1655423999@www.pharmajournalist.com
SUMMARY:2nd HER2-Targeted Therapies Summit
DESCRIPTION:Outcomes for HER2-expressing breast cancer are patients constantly improving; advancements in diagnostics\, trial design and innovative drug design are at an all-time high; complementing the newly accessible HER2 ‘low’ space and wider range of tumor indications; the last year has given us more progress in HER2-targeted therapies than ever before. \nAs such\, the HER2-Targeted Therapies Summit returns for its second year as the only industry-dedicated forum for large pharma\, biotech and academia to unite under one roof to discuss these developments\, gain competitive insights and ultimately turbocharge practice-changing anti-HER2 drugs to patients. \nAs the clinical and commercial opportunity of HER2-targeted therapies becomes apparent\, join us to connect with over 80+ HER2 experts and expand the clinical utility of your pipeline by exploring HER2 as a multi-tumor target. \nView the full agenda now: https://ter.li/kxq80g
URL:https://www.pharmajournalist.com/event/2nd-her2-targeted-therapies-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220614
DTEND;VALUE=DATE:20220617
DTSTAMP:20260515T180613
CREATED:20220207T102442Z
LAST-MODIFIED:20220207T102621Z
UID:33181-1655164800-1655423999@www.pharmajournalist.com
SUMMARY:2nd Tumor Myeloid-Directed Therapies Summit
DESCRIPTION:Returning in 2022\, the 2nd Tumor Myeloid-Directed Therapeutics Summit is the only industry-focused meeting dedicated to unlocking novel therapeutic potential through the myeloid compartment. \nThis is your ultimate forum to identify\, validate\, and clinically progress myeloid targets to expand the oncologists toolkit and realize better responses by engaging myeloid anti-tumor function. \nDesigned for experts working directly on myeloid-directed therapies\, and those in adjacent immuno-oncology fields\, from cell therapy to checkpoint and engager development. \nIf you’re scratching your head in attempt to enhance efficacy in solid tumors and overcome barriers in the microenvironment\, this is your 500-foot view of the intricate pathways\, interactions\, and novel target development in the tumor microenvironment \nDeep-dive into myeloid biology\, guided by 27+ industry Gurus from the likes of Pionyr Therapeutics\, Gilead Sciences\, Merck\, Verseau Therapeutics\, Carisma Therapeutics\, Pfizer and many more \nWith targets such as TREM1 and TREM2 making waves in the clinic\, analysis of CD47 candidates back-translating to next-generation therapies\, and novel dendritic cell candidates such as FTL3 in development\, this 3-day myeloid extravaganza is unmissable for anyone looking to unlock better therapeutic potential through the myeloid compartment. \nTo know more visit: https://ter.li/2067lj
URL:https://www.pharmajournalist.com/event/2nd-tumor-myeloid-directed-therapies-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220620
DTEND;VALUE=DATE:20220622
DTSTAMP:20260515T180613
CREATED:20220307T120117Z
LAST-MODIFIED:20220307T120117Z
UID:33518-1655683200-1655855999@www.pharmajournalist.com
SUMMARY:2nd Inner Ear Disorders Therapeutics Summit
DESCRIPTION:Biotech companies are paving the way to displace the cochlear implant and cater for the huge unmet need in hearing and balance disorders. The field is booming with excitement\, with pharma companies increasing investment into these pipelines in the race to successfully reverse hearing damage. \n \nReturning as an in-person event to Boston\, the 2nd Inner Ear Disorders Therapeutics Summit will unite drug developers focusing on preventative and regenerative approaches targeting the inner ear. \nDebate the clinical applicability of different modalities\, including small molecule\, stem cell and gene therapy; accurately monitor hearing loss progress\, successfully identify new targets\, optimize preclinical models\, discuss combination strategies for drugs and devices and hear the latest clinical updates and novel translatable research of the inner ear. \nJoin over 100 drug developers from the likes of Otonomy\, Sound Pharmaceuticals\, Frequency Therapeutics\, Astellas\, Sensorion\, Decibel Therapeutics and more at this 4-day disease-agnostic\, modality-agnostic event designed specifically for industry-based experts in inner ear disorders to successfully translate their therapeutics into the clinic. \nTo know more visit: https://ter.li/1wvymk
URL:https://www.pharmajournalist.com/event/2nd-inner-ear-disorders-therapeutics-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220621
DTEND;VALUE=DATE:20220624
DTSTAMP:20260515T180613
CREATED:20211018T092448Z
LAST-MODIFIED:20211203T090456Z
UID:31841-1655769600-1656028799@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China 2022
DESCRIPTION:CPhI & P-MEC China is Asia’s leading pharmaceutical show for trading\, knowledge sharing and networking. It spans all industry sectors along the pharmaceutical supply chain and is your one-stop platform to grow business in the 2nd largest pharma market in the world. CPhI & P-MEC China 2022\, with the co-located shows FDF\, bioLIVE\, Pharma Excipients\, NEX and LABWORLD China\, etc. is expected to draw near 3\,000 exhibitors and hundreds and thousands of professionals from the pharmaceutical industry. \nTo know more visit: https://bit.ly/3n5sp8w
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-2022/
LOCATION:SNIEC\, Shanghai\, China
ORGANIZER;CN="Informa Markets":MAILTO:Candice.lau@informa.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220621
DTEND;VALUE=DATE:20220624
DTSTAMP:20260515T180613
CREATED:20220228T114841Z
LAST-MODIFIED:20220228T114841Z
UID:33407-1655769600-1656028799@www.pharmajournalist.com
SUMMARY:7th Microbiome Movement - Drug Development Summit
DESCRIPTION:The 7th Microbiome Movement – Drug Development Summit returns to Boston at a pivotal time. As the microbiome therapeutic space matures\, with more indications being pursued and more companies conducting trials\, the focus of this event – now in its 7th year – is evolving to showcase these new studies. With this progress however comes new challenges\, and we’re excited to once again be uniting over 300 microbiome pioneers to work towards overcoming these challenges and moving the whole industry closer to commercial approval. \nContinuing to unite the most forward-thinking researchers from the biopharmaceutical industry\, our unrivaled program will uncover microbiome functionality and mechanisms\, decipher translation issues and advance clinical development\, overcome the key GMP manufacturing and scale-up challenges\, whilst also discovering and applying microbiome biomarkers for improved clinical outcomes. \nThis event is the most comprehensive forum for microbiome drug developers and the perfect opportunity for the industry to take a collaborative approach to close the clinical gap\, discover the next generation of microbiome-based therapeutics\, and establish new partnerships to accelerate your research. \nTo know more visit: https://bit.ly/3hss4dD
URL:https://www.pharmajournalist.com/event/7th-microbiome-movement-drug-development-summit/
LOCATION:Revere Boston Common\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@microbiome-movement.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220621
DTEND;VALUE=DATE:20220624
DTSTAMP:20260515T180613
CREATED:20220412T093427Z
LAST-MODIFIED:20220412T093427Z
UID:33768-1655769600-1656028799@www.pharmajournalist.com
SUMMARY:Non-Viral RNA Delivery Systems Summit
DESCRIPTION:Built with biopharmaceutical industry insights\, this in-person conference will delve into the latest advancements of non-viral RNA delivery systems such as LNPs\, exosomes and polymers to set the scene for the translation of targeted\, safe and durable delivery systems for RNA therapeutics and vaccines with improved formulation\, distribution and tissue-specificity. \nDon’t miss 20+ pioneering speakers from large pharma\, innovative biotech\, and KOLs of academia who are shaping the landscape of advanced and emerging non-viral RNA delivery systems for the RNA biopharma community worldwide.  \nJoin this meeting to hear cutting-edge science and latest data on: \n\nExpand Therapeutic Applications with Emerging Non-Viral RNA Delivery Systems\nDiscover Novel LNP & Alternative Technologies to Increase Specificity & Efficacy\nLearn About the Latest Improvements of Non-Viral Delivery Systems for the Delivery of a Broad Range of RNA Payloads\nIncrease Tissue Specific & Extrahepatic Delivery through Optimizing Formulation & Design\nDelve into the emerging Engineering\, Formulation & Packaging Methods to Improve Non- Viral RNA Delivery & Stability\n\nJoin 80+ VPs\, Heads and Directors of RNA delivery\, Formulation and Process development for a deep dive into delivery challenges and strategies of non-viral systems to fully unleash the therapeutic opportunities offered by different RNA therapeutics and vaccines. \nTo know more visit: https://ter.li/ai0qwx
URL:https://www.pharmajournalist.com/event/non-viral-rna-delivery-systems-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220627
DTEND;VALUE=DATE:20220630
DTSTAMP:20260515T180613
CREATED:20220407T094504Z
LAST-MODIFIED:20220407T094504Z
UID:33743-1656288000-1656547199@www.pharmajournalist.com
SUMMARY:3rd TCR-based Therapies for Solid Tumors Summit
DESCRIPTION:Are you using TCRs to target solid tumors yet? \nWith Immunocore having achieved commercialization for the first TCR therapy and Adaptimmune hot on their tail\, 2022 is fast becoming the year for TCRs. \nJoin the TCR-based Therapies for Solid Tumors Summit (June 27-29) to gain knowledge to accelerate the clinical development and improve the safety of these game-changing cell therapies. \nFeaturing 24+ expert speakers\, over 80% of whom are new for 2022\, this summit will address the toughest challenges in TCR development\, such as improving TCR discovery and efficacy\, combating the tumor microenvironment\, optimizing target selection and advancing manufacturing\, preclinical and clinical processes. \nJoin leaders in the field\, including Adaptimmune\, Iovance and TScan as they examine methods to prevent cross reactivity\, increase cell fitness and infiltration\, improve therapy safety and ultimately overcome the hurdles holding back these game-changing treatments from patients in need. \nFind out more in the Event Guide: https://ter.li/sa0pnw
URL:https://www.pharmajournalist.com/event/3rd-tcr-based-therapies-for-solid-tumors-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220628
DTEND;VALUE=DATE:20220701
DTSTAMP:20260515T180613
CREATED:20220427T101322Z
LAST-MODIFIED:20220427T101322Z
UID:33919-1656374400-1656633599@www.pharmajournalist.com
SUMMARY:11th Annual HPAPI Summit
DESCRIPTION:Undoubtedly\, the past two years have changed the pharma industry forever; new modalities are dominating pharma pipelines\, drugs are increasing in potency\, and the restrictions around product quality are tighter than ever before. \nIt is integral that the HPAPI community comes together to apply expertise in ensuring operator safety\, alongside product quality\, to the future of hazardous drug production and fully understand this new landscape\, and regulatory environment. Built in collaboration with industry experts\, the HPAPI Summit provides end-to end coverage tackling; development\, commercial manufacturing & tech transfer\, occupational toxicology\, industrial hygiene & EHS\, across small molecules\, large molecules\, drug conjugates & ATMP\, for a holistic approach to bullet-proofing your hazardous drug production. \nWith sessions championed from the likes of Merck\, Bayer\, AstraZeneca\, Takeda and more\, don’t miss this opportunity to reconnect\, reassess and re-enforce your risk management for your potent pipeline and production at the longest standing and largest global summit for highly potent API’s & hazardous drugs. \nSave up to $700 on your event pass when you book before Friday\, May 20. \nGroup discounts of up to 20% are also available when you bring your team! \nTo know more visit: https://ter.li/3csco9
URL:https://www.pharmajournalist.com/event/11th-annual-hpapi-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220706
DTEND;VALUE=DATE:20220708
DTSTAMP:20260515T180613
CREATED:20220126T093554Z
LAST-MODIFIED:20220303T093817Z
UID:32980-1657065600-1657238399@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Europe
DESCRIPTION:The 8th Annual Microbiome Connect: Europe 2022 dedicated to showcasing the leading drug development and consumer product platforms applying live microbial consortia\, engineered microbes\, and microbial-derived metabolites for therapeutic and health applications in patients and consumers. \nAs the first EMA approved microbiome-targeted therapeutics emerge on the horizon\, drug developers will have to opportunity to benchmark their rational drug platforms\, targeting validated pathways in gastrointestinal\, neurological\, metabolic disorders\, as well as oncology-based indications. \nFurthermore\, there will be separate tracks dedicated to developing novel\, clinical-validated product formulations for nutritional\, digestive wellness\, oral and skincare applications. \nJoin the microbiome field to hear from biotechs\, pharma voices\, investment bodies\, consumer product brands and more\, on how to develop robust\, scalable\, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market. \nTo know more visit: https://hubs.ly/Q012R7H40
URL:https://www.pharmajournalist.com/event/microbiome-connect-europe/
LOCATION:Amsterdam
ORGANIZER;CN="Kisaco Research":MAILTO:Jessica.Mockler@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220711
DTEND;VALUE=DATE:20220714
DTSTAMP:20260515T180613
CREATED:20220330T093536Z
LAST-MODIFIED:20220623T094708Z
UID:33675-1657497600-1657756799@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Neurological Disorders Europe
DESCRIPTION:Accelerating Europe’s Progress in CNS Gene Therapy \nNavigating Europe-Specific Challenges & European Regulators Requirements; Optimizing Preclinical Research in Neurological Models & Revolutionizing Gene Therapy Delivery to CNS Targets in the Clinic \nAs programs advance globally\, the 3rd Annual Gene Therapy for Neurological Disorders Europe meeting is the industry’s definitive forum dedicated to showcasing the European landscape’s progress and specific regulatory challenges as they move from rare neurological disorders to targeting more common diseases including Parkinson’s\, epilepsy and neurodevelopmental disorders. \nReturning as its first in-person meeting\, with brand new speakers and companies joining the conversation\, attend alongside 100 fellow preclinical\, translational\, clinical and commercial gene therapy experts to overcome your translational challenges and improve the delivery of your gene therapy to its CNS target\, and optimize your European strategy as you move from rare to common patient populations. \nTo know more visit: https://ter.li/l4b1t3
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-neurological-disorders-europe/
LOCATION:Paris Marriott Charles de Gaulle Airport Hotel\, Zone Hoteliere\, 5 All. du Verger\, Roissy-en-France\, 95700
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220711
DTEND;VALUE=DATE:20220714
DTSTAMP:20260515T180613
CREATED:20220412T094733Z
LAST-MODIFIED:20220412T094733Z
UID:33773-1657497600-1657756799@www.pharmajournalist.com
SUMMARY:Digital Biomarkers and Clinical Measures in Neurology Summit
DESCRIPTION:The Digital Biomarkers & Clinical Measures in Neurology Summit is the definitive industry forum sharing cross-industry insight to transform clinical development with digital data. \nFrom integrating wearable technologies\, smartphone apps\, and speech-based digital biomarkers into remote clinical research to elucidating pathways to clinical validation to establish therapeutic efficacy\, join industry experts from Merck\, Janssen\, GSK\, Sanofi\, Novartis\, Takeda\, Eli Lilly & Company\, Mitsubishi Tanabe Pharma Holdings America and many more to improve patient retention and establish efficacy with richer datasets. \nTo know more visit: https://ter.li/mk4lmh
URL:https://www.pharmajournalist.com/event/digital-biomarkers-and-clinical-measures-in-neurology-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220712
DTEND;VALUE=DATE:20220715
DTSTAMP:20260515T180613
CREATED:20220413T082618Z
LAST-MODIFIED:20220413T085216Z
UID:33780-1657584000-1657843199@www.pharmajournalist.com
SUMMARY:3rd GxP Cloud Compliance Summit
DESCRIPTION:Migrate Your GxP Regulated Applications to the Cloud with Compliance\, Security\, & Quality Assurance  \nWith hot anticipation for the FDA’s new CSA guidance\, life science companies have the opportunity to take a proactive stance in their approach to the new methodologies. In the climate of this exciting new era of computer systems validation\, join over 100 Life Science\, IT & Quality professionals at the 3rd GxP Cloud Compliance Summit. \nEmulating on 2021’s success\, the 3rd GxP Cloud Compliance Summit is excited to return in July\, for the first time in person! \nThis is your only opportunity to develop and implement a practical roadmap to migrate your GxP regulated applications to the cloud with real-life insights from regulatory\, security and quality experts from leading life science companies\, as well as cloud providers\, auditors\, and industry regulators. \nWith the FDA strongly advising life science organizations to start getting ready for CSA now\, join us in July to discover how your business can get ahead and simplify the transition process. \nTo know more visit: https://ter.li/uichgz
URL:https://www.pharmajournalist.com/event/3rd-gxp-cloud-compliance-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220712
DTEND;VALUE=DATE:20220715
DTSTAMP:20260515T180613
CREATED:20220427T072259Z
LAST-MODIFIED:20220427T072259Z
UID:33913-1657584000-1657843199@www.pharmajournalist.com
SUMMARY:BCMA Targeted Therapies Summit
DESCRIPTION:With the undeniable excitement in the BCMA field over the past few months\, the BCMA-Targeted Therapies Summit returns to the space to equip you with the knowledge and connections to revolutionize your BCMA-centered pipeline. \nPick the brains of 90+ academic and industry pioneers at the first physical edition of the only meeting dedicated to supercharging transformative next generation BCMA-targeted therapies into the clinic\, navigating the complex landscape and optimizing clinical strategy to revolutionize treatment of multiple myeloma and beyond. \nHear from leading speakers including: \n\n\n\nSuzette Girgis\, Senior Director & Head of Clinical Pharmacology & Hematologic Malignancies\, Johnson & Johnson Services\nEric Fedyk\, Global Program Leader of BCMA Assets\, 2seventy bio\nDavid DiLillo\, Director\, Immuno-Oncology\, Regeneron\nBrandon Kremer\, Group Senior Medical Director\, Clinical Development Lead\, GlaxoSmithKline\nNathan Martin\, Translational Scientist & Project Lead\, Bristol Myers Squibb\nMike Damore\, Director & Lead – Translational Oncology\, Pfizer\nChetasi Talati\, Medical Director\, AbbVie\nDexiu Bu\, Senior Principle Scientist\, CART group\, Immuno-Oncology & Hematology\, Novartis\nFaiza Zafar\, Senior Medical Science Liaison\, Legend Biotech\n\n\n\nTake a look at the full event guide to learn more.
URL:https://www.pharmajournalist.com/event/bcma-targeted-therapies-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220713
DTEND;VALUE=DATE:20220715
DTSTAMP:20260515T180613
CREATED:20220323T103153Z
LAST-MODIFIED:20220324T101902Z
UID:33612-1657670400-1657843199@www.pharmajournalist.com
SUMMARY:Advanced Wound Care Summit
DESCRIPTION:The Advanced Wound Care Innovation Summit is the first industry-led forum focused on delivering innovative wound care treatments to patients. Expect to hear from\, and discuss with\, world leaders of wound care research who are driving the development of novel biomaterials\, remote-monitoring devices\, and digital health management solutions. \nFind out how C-level Executives\, VPs and Directors of R&D are tackling the most pressing industry challenges and seizing new growth opportunities. Whether an executive\, investor\, researcher or healthcare professional\, this meeting offers an empowering environment that allows you to make wound care decisions with confidence. \nTo know more visit: www.advancedwoundcareusa.com
URL:https://www.pharmajournalist.com/event/advanced-wound-care-summit/
LOCATION:Boston\, MA (Venue TBD)
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220715
DTEND;VALUE=DATE:20220717
DTSTAMP:20260515T180613
CREATED:20220126T093119Z
LAST-MODIFIED:20220126T093119Z
UID:32975-1657843200-1658015999@www.pharmajournalist.com
SUMMARY:RNA Therapeutic Modalities Summit USA
DESCRIPTION:The RNA Therapeutic Modalities Summit is North America’s only industry led conference covering clinical progress and commercial scale development for the full spectrum of RNA therapeutic approaches. \nOur agenda will featuring the pioneering biotechs translating current vaccine success into further clinically validated treatments in broader indications using RNA technologies such as antisense oligonucleotides\, aptamers\, small interfering RNAs (siRNAs)\, microRNAs\, and messenger RNA (mRNA). \nThere will be dedicated discussion on the rationale for different mechanisms-of-action\, how to optimise the power and versatility of RNA-based constructs\, and the progress to date in disease indications encompassing neurodegeneration\, metabolic and cardiovascular disorders and various cancers. \nIf your R&D teams are looking to establish a differentiated drug platform through RNA modification and delivery systems\, improve stability\, delivery and durability of current drug candidates\, or enable tissue-specific administration with higher targeting ability and less toxicity\, make sure they secure a place at this hotly anticipated conference. We look forward to welcoming you to Boston for dedicated in-person networking in June! \nTo know more visit: https://hubs.ly/Q012R75G0
URL:https://www.pharmajournalist.com/event/rna-therapeutic-modalities-summit-usa/
LOCATION:Boston\, USA
ORGANIZER;CN="Kisaco Research":MAILTO:Jessica.mockler@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220718
DTEND;VALUE=DATE:20220721
DTSTAMP:20260515T180613
CREATED:20220304T093223Z
LAST-MODIFIED:20220621T095620Z
UID:33445-1658102400-1658361599@www.pharmajournalist.com
SUMMARY:2nd Annual Next Generation Gene Therapy Vectors Summit
DESCRIPTION:Overcome First Generation Gene Therapy Vector Challenges To Guarantee Targeted\, Specific\, Efficient & Safe Gene Delivery \nThe 2nd Next Generation Gene Therapy Vectors Summit is dedicated to overcoming the current immunogenicity\, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors to deliver safe and efficacious gene therapy products. \nIndustry pioneers from cutting edge biopharma and world-leading academic vectorology groups are set to share clinically meaningful insights on how to enhance existing vectors and pioneer radical novel approaches to deliver genes more efficiently and safely. \nSpanning a range of delivery approaches from cutting-edge AAV capsid optimization\, utilizing lenti and other viral vectors\, to innovative non-viral gene therapy approaches\, this comprehensive event will enable you to reduce immunogenicity\, improve tissue targeting\, simplify manufacturing and enhance the safety profile of your approach. \nEverything in gene therapy starts with delivery\, so join this definitive\, niche conference to delve into the details of vector design\, engineering and optimization case studies\, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before. \nTo know more visit: https://ter.li/3mccj3
URL:https://www.pharmajournalist.com/event/2nd-annual-next-generation-gene-therapy-vectors-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220718
DTEND;VALUE=DATE:20220721
DTSTAMP:20260515T180613
CREATED:20220613T095312Z
LAST-MODIFIED:20220613T095312Z
UID:34412-1658102400-1658361599@www.pharmajournalist.com
SUMMARY:LEAP HR Life Sciences East
DESCRIPTION:LEAP HR: Life Sciences East 2022 Conference will be taking place as an in-person event in Boston\, July 18-20. Returning as a physical event for its seventh year\, this event will showcase 35+ case studies of how life sciences organizations of all stages and sizes are redefining post-pandemic best practices and turbocharging the employee experience to meet the holistic and previously unmet needs of your in-demand life science workforce. \nThis is a unique chance to take advantage of a combination of plenary sessions\, breakout sessions\, panels and roundtable discussions specifically designed to solve your biggest HR challenges and deliver actionable insights for HR innovation. \nNetwork with 250+ other strategic HR leaders working within life sciences on the East Coast and surrounding areas and join a support network of 500+ life science HR leaders who have previously taken part. \nYou’ll hear from companies such as: Takeda\, Novo Nordisk\, AstraZeneca\, Pfizer\, Alexion Pharmaceuticals\, Regeneron Pharmaceuticals\, Alnylam Pharmaceuticals\, BioNTech\, Ipsen\, Novartis\, PTC Therapeutics\, TCR2 Therapeutics\, Ginkgo BioWorks and more… \nFind out more by visiting the website: https://leap-hr-lifesciences-east.com/
URL:https://www.pharmajournalist.com/event/leap-hr-life-sciences-east/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220725
DTEND;VALUE=DATE:20220728
DTSTAMP:20260515T180613
CREATED:20220526T184152Z
LAST-MODIFIED:20220526T184152Z
UID:34241-1658707200-1658966399@www.pharmajournalist.com
SUMMARY:Cell Therapy Potency Assay Summit
DESCRIPTION:Cell Therapy Potency Assay Summit\, taking place from 25-27 of July in Boston\, will bring together professionals working in analytical development\, quality\, regulatory and process development functions. \nJoin your peers to: \n\nBrainstorm best-in-class approaches to overcome variability in QC\nCompare next gen approaches from cytotoxicity to omics\nDevelop reference standards to benchmark across the industry\nCreate an assay with commercialization in mind.\n\nThis summit will equip you with the tools you need to fast track your regulatory submissions and ease through clinical development. \nYou can view the event guide here: https://ter.li/6a13vg \nSecure your place at the summit here: https://ter.li/zp17ep \nWe are looking forward to welcoming you to Boston this July!
URL:https://www.pharmajournalist.com/event/cell-therapy-potency-assay-summit/
LOCATION:The Bostonion\, 26 North Street\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260515T180613
CREATED:20220407T101301Z
LAST-MODIFIED:20220413T091417Z
UID:33748-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:3rd Gamma Delta T Therapies Summit
DESCRIPTION:The data has dropped and 2022 has been touted as a monumental year for γδT Therapies \nWith Adicet Bio\, In8Bio\, Gamma Delta Therapeutics\, Lava Therapeutics\, and ImCheck Therapeutics releasing clinical data from engineered and antibody-based γδT Therapy in patients; the race to market for the first allogeneic and solid tumor-targeting γδT Therapy is truly on. \nJoin the 3rd Gamma Delta T Therapies Summit to learn and network with 120+ of the world’s leaders including γδT pioneer\, Adrian Hayday\, and together accelerate the development of effective\, persistent\, globally accessible cell therapy for solid tumors. \nTake a look at the official program here. \nEnhance cytotoxicity\, discover novel targets\, engineer stealth and persistence\, interrogate cell subsets\, and scale-up manufacturing through a deep understanding of the fundamental biology and target product profile for γδT therapies. \nIndustry experts agree that this year\, the γδT is the cell to know. Ensure you and your team are ahead of the curve and equipped with the need-to-know insights to advance successful therapeutics\, across 2 dedicated tracks covering Discovery\, Process Research\, Preclinical\, and Clinical Development; as well as 3 deep-dive workshops\, and a Gamma Delta 101 Bootcamp.
URL:https://www.pharmajournalist.com/event/3rd-gamma-delta-t-therapies-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260515T180613
CREATED:20220407T101551Z
LAST-MODIFIED:20220413T091500Z
UID:33751-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:3rd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit
DESCRIPTION:The 3rd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit is the only industry-led forum focused on the therapeutic opportunity of drugs directed against B-cell\, plasma cell\, and T-cell targets in autoimmunity. \n \nSeveral drug approvals for B-cell directed therapies have made waves in autoimmune drug development. As investment and industry momentum increases\, this summit will once again unite the movers and shakers of the B&T cell-mediated autoimmune space with the likes of Pfizer\, Nurix\, Regeneron\, Gossamer Bio\, and more. \nTake a look at the 2022 program here. \nAttending this summit is a unique opportunity to be involved in interactive discussions on: \n\nOvercoming challenges of heterogeneity of disease models and demonstrating B cell activation in tissues\nEmerging therapies including B-cell specific therapies\, tolerizing approaches\, small molecule drugs\, engineered cell immunotherapy\, B&T cell checkpoint targeting\, FcRn inhibition\, as well as PROTAC/degrader approaches\nTherapeutic opportunities across both peripheral and tissue specific autoimmune diseases\nOvercoming clinical challenges of treating B&T cell mediated autoimmune diseases through combinatorial regimens that target T-cell co-stimulation\, leveraging autoantibody signatures to identify patient responders and discussing autoimmune disease biomarkers\n\nAs the space grapples with translational and early clinical drug development challenges\, join this comprehensive forum 80+ key leaders and decision-makers to harness the immune system and conquer B&T cell mediated autoimmune diseases.
URL:https://www.pharmajournalist.com/event/3rd-annual-b-t-cell-mediated-autoimmune-disease-drug-development-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220730
DTSTAMP:20260515T180613
CREATED:20220425T085640Z
LAST-MODIFIED:20220425T085640Z
UID:33898-1658793600-1659139199@www.pharmajournalist.com
SUMMARY:Cytokine-Based Drug Development Summit
DESCRIPTION:The 3rd Cytokine-Based Drug Development Summit has been developed following extensive research to address YOUR biggest challenges in the cytokine field. \nWith 30+ expert speakers\, including the hottest academic researchers and leading figures from the industry\, this 4-day program is your opportunity to gain insight into the latest clinical advancement and have thought provoking discussions around how to overcome the fields greatest drug development challenges. \nWhat can you expect to see? \n\nFurther your understanding of the underlying mechanisms of action\, and T-cell exclusion from the tumor in order to turn cold tumors ‘hot’ with Ask-Gene Pharma\nOptimize cytokine engineering to ensure stability and improve the favorable risk benefit profile with Proviva Therapeutics\nLeverage insights from industry’s leading lights to overcome toxicity challenges by ensuring tumor targeting is selective and therefore enhances the anti-tumor response with Equilium\, Cytonus Therapeutics & Cytimmune\nTake a deep dive into preclinical cancer models covering both in vitro and in-vivo studies and how these are unveiling the most favoured pharmaceuticals properties of therapeutic cytokines with Astra Zeneca & Xilio Therapeutics\nUncover the latest data coming out of the clinic of cytokines in combination with checkpoint inhibitors and monoclonal antibodies with Alkermes & NeoImmune Tech\n\nGet your copy of the brand-new agenda for the full list of speakers and sessions.
URL:https://www.pharmajournalist.com/event/cytokine-based-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260515T180613
CREATED:20220509T102858Z
LAST-MODIFIED:20220509T102858Z
UID:34021-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:2nd Annual mRNA-Based Therapeutics Summit
DESCRIPTION:Do you want to be part of the largest gathering of mRNA professionals? \nThe 2nd Annual mRNA-Based Therapeutics Summit is returning in-person to Boston this July 26-28. \nExpect exclusive data from the movers and shakers in mRNA vaccine and therapy development\, 75+ world-class speakers\, 5 dedicated tracks of content and 45+ deep-dive case studies. Find out more in the full event guide: https://ter.li/yc800m \nHere’s a snapshot of the expert speakers you can hear from: \n\n​​​​Kathy Fernando\, VP\, Head of Worldwide Research\, Development and Medical Operations & Head of mRNA Scientific Planning\, Pfizer\nRegis Gervier\, Global Head\, mRNA Center of Excellence\, Sanofi\nRituparna Das\, VP – COVID Vaccines\, Moderna\nHao Chen\, Global Head of Cell & Viral Drug Substance\, GlaxoSmithKline\nJoe Payne\, Founder\, President & CEO\, Arcturus Therapeutics\nPervin Anklesaria\, Deputy Director\, HIV Vaccines & Biologics\, Bill & Melinda Gates Foundation\nManmohan Singh\, SVP – Pharmaceutical Sciences & Delivery Technologies\, Beam Therapeutics\nAkhilesh Bhambhani\, Senior Director – Biologics Drug Product Development; Tech Dev/Tech Ops\, Ultragenyx\nLiang Shang\, Senior Scientist – Vaccine Analytical\, Merck\nRussell Johnson\, VP – Formulation Research\, RVAC Medicines\nTamar Grossman\, Global Head – RNA & Targeted Therapeutics\, The Janssen Pharmaceutical Companies of Johnson & Johnson\n\nDownload the official brochure to discover why Sanofi\, Ultragenyx\, Beam Therapeutics\, Pfizer\, Moderna\, Merck\, Eli Lilly\, GSK\, and 300+ others have already secured their places.  https://ter.li/yc800m
URL:https://www.pharmajournalist.com/event/2nd-annual-mrna-based-therapeutics-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220726
DTEND;VALUE=DATE:20220729
DTSTAMP:20260515T180613
CREATED:20220518T092848Z
LAST-MODIFIED:20220518T092848Z
UID:34131-1658793600-1659052799@www.pharmajournalist.com
SUMMARY:iPSC Manufacturing Summit
DESCRIPTION:With iPSCs exhibiting game-changing potential in the bid to develop an off-the-shelf therapy\, the brand-new iPSC Manufacturing Summit is the only summit dedicated to solving the manufacturing\, quality and analytical challenges hindering your iPSC-derived treatments from reaching patients. \nThis forum will unite the exclusive community advancing the production of high-quality and consistent iPSC products\, with in depth case studies aimed to develop optimal differentiation\, cryopreservation\, and analytical protocol to enhance process development to ensure it is robust\, rapid and repeatable. \nOur 17+ expert speakers will be addressing methods to enhance potency testing and cell characterization\, enhance iPSC product quality\, and integrate successful gene-editing into your manufacturing. \nTake a look at the full event guide to learn more.
URL:https://www.pharmajournalist.com/event/ipsc-manufacturing-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR